A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations
Status:
Completed
Trial end date:
2021-01-16
Target enrollment:
Participant gender:
Summary
This is a phase 1, randomised, open-label, three-way, three-period, crossover relative
bioavailability study to assess the single-dose pharmacokinetics of FOR-6219 in capsule and
tablet formulations in postmenopausal women. The effect of high-fat food on the
pharmacokinetics of the tablet formulation will also be evaluated. A total of twelve,
post-menopausal women, will be randomised to receive a single oral dose of FOR-6219 in three
treatment periods: capsule formulation (fasted); tablet formulation (fed); tablet formulation
(fasted)